Crossmark

A two-faced selectivity solution to target SMARCA2 for cancer therapy

Crossref DOI link: https://doi.org/10.1038/s41467-023-36238-0

Published Online: 2023-01-31

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Harling, John D. https://orcid.org/0000-0003-3602-324X
Tinworth, Christopher P. https://orcid.org/0000-0002-2756-707X
License Information

Text and Data Mining valid from 2023-01-31

Version of Record valid from 2023-01-31
More Information

Article History

Received: 13 December 2022

Accepted: 16 January 2023

First Online: 31 January 2023

Competing interests

: The authors declare no competing interests.